NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

In connection with the leadership transition, Lars Rebien Sørensen, Chair of the Novo Nordisk Foundation and former CEO of NVO, will initially join the company’s board as an observer ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Novo Nordisk's new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated ...